z-logo
Premium
Clinical implications of SARS‐CoV‐2 cycle threshold values in solid organ transplant recipients
Author(s) -
Gaston David C.,
Malinis Maricar,
Osborn Rebecca,
Peaper David R.,
Landry Marie,
JuthaniMehta Manisha,
Azar Marwan M.
Publication year - 2021
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.16357
Subject(s) - medicine , covid-19 , solid organ , organ transplantation , sars virus , intensive care medicine , virology , transplantation , infectious disease (medical specialty) , disease , outbreak
Detection of SARS‐CoV‐2 viral RNA by RT‐PCR assays is the primary diagnostic test for COVID‐19. Cycle threshold (C T ) values generated by some of these assays provide inversely proportional proxy measurements of viral load. The clinical implications of C T values are incompletely characterized, particularly in solid organ transplant (SOT) recipients. We conducted a retrospective chart review of 25 adult SOT recipients admitted to the Yale New Haven Health System between March 1 and May 15, 2020, analyzing 50 test results to investigate the clinical implications of SARS‐CoV‐2 C T values in this population. Initial C T values from upper respiratory tract samples were significantly higher in patients on tacrolimus, but were not associated with admission severity nor highest clinical acuity. Viral RNA was detected up to 38 days from symptom onset with a gradual increase in C T values over time. In five patients with serial testing, C T values <35.0 were detected >21 days after symptom onset in 4/5 and ≥27 days in 2/5, demonstrating prolonged RNA detection. These data describe SARS‐CoV‐2 viral dynamics in SOT patients and suggest that C T values may not be useful to predict COVID‐19 severity in SOT patients. SARS‐CoV‐2 C T values may be more useful in informing infection prevention measures.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here